ZEBRA BIOLOGICS INC
Relaxin-IgG fusion protein (H2-PiP) using Protein-in-Protein antibody technology for extended half-life RXFP1 agonist therapy
- Sector
- Biotech
- Headquarters
- Concord, MA
- Founded
- 2013
- Latest Form D
- $3M, Dec 2015
- Total capital
- $13.3M
- Federal grants
- $1.3M
- 5 awards · 2019–2021
- Rank in peer group#232 of 502
- Private capital raised
- $12M
- 3 Form D · last Dec 2015
- 131 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 1 pending · first 2021
- Rank in peer group#57 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Engineering a long-acting relaxin agonist to treat liver fibrosis$309K
- Federal grantHealth and Human S · Phase I · Engineering a long-acting relaxin agonist to treat liver fibrosis$309K
- Federal grantHealth and Human S · Phase I · Treatment of diabetic retinopathy with TrkB agonist antibodies$211K
- Federal grantHealth and Human S · Phase I · Treatment of diabetic retinopathy with TrkB agonist antibodies$211K
- Federal grantHealth and Human S · Phase I · Discovery of TrkC agonist antibodies for hearing loss$304K
- Private capital raisedForm D · SEC · 3rd filing$3M
- Private capital raisedForm D · SEC · 2nd filing$9M
- Private capital raisedForm D · SEC · 1st filing$450
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#232 · top 46%
- Granted patents#57 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Richard A. LernerResearcherDirectorLinked by 1 patent
- Ronald M. LindsayResearcherExecutive Officer, DirectorLinked by $309K in grants as PI
- Feng A. GaoDirectorNamed in SEC Form D filings
- Phillip M. FrostDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 2- GrantedTRKB AGONIST ANTIBODIES AND METHODS FOR TREATING AN OCULAR DEGENERATIVE DISORDER CHARACTERIZED BY DEGENERATION OF RETINAL GANGLION CELLS (RGCs)USPTOUS 10,975,152
- PendingTrkb Agonist Antibodies For Treating Neurodegenerative DisordersUSPTOApplication PCTUS2017030570
Related companies, and why
- AGEX THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- THIRD ELEMENT BIO INC.Similar federal contract value in Biotech · null in contracts
- FLUGEN, INC.Similar federal contract value in Biotech · null in contracts
- CAPRICOR, INC.Similar federal contract value in Biotech · null in contracts
- ONCOTRAP INCSimilar federal contract value in Biotech · null in contracts
- PolyCore Therapeutics LLC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .